Remarkably, our results are in concordance with former studies revealing tau pathology is exceedingly reflective of cognitive decline in AD indicating that Nobiletin may be an efficient therapy targeting phosphorylated tau and preceding to cognitive enhancement (Berg et al. 1998; Arriagada et al. 1992). Here, MAPT is linked to Alzheimer disease.